Aisling Capital related stories
All articles and analysis
Foresite Capital leads Series B round for Allergen Research CorpSan Mateo, California-based Allergen Research Corp, which develops treatments for food allergies, has closed $80 million in Series B funding. Foresite Capital led the round with participation from Longitude Capital, Fidelity Management & Research Company, Aisling Capital, Adage Capital, RA Capital Management and Palo Alto Investors. In conjunction with the funding, Dr. Jim Tananbaum, CEO and managing director of Foresite Capital and Stacey Seltzer, a partner at Aisling Capital, have been added to ARC's board of directors.
- Cidara Therapeutics snags $42 mln Series B
San Diego-based biotech firm Cidara Therapeutics Inc has closed $42 million in Series B funding. The investors in this round were not named; however, the firm's previous backers include 5AM Ventures, Aisling Capital, Frazier Healthcare and InterWest Partners.
IPO Profile: Dermira IncThe drug company had a market cap of about $300 million when it went public
Small fund approach brings results to NY pension: VCJMoney manager sees strong gains with IVP, Aisling, JP Morgan funds.
Syros Pharmaceuticals snags $53 mln from Polaris, Flagship, ARCH VentureWatertown, Mass.-based Syros Pharmaceuticals, which focuses on treating cancer and other diseases, has raised $53 million in Series B funding.
Fund performance: Small fund approach brings results to NY pensionMoney manager sees strong gains with IVP, Aisling, JP Morgan funds
- PE-backed LENSAR expands board with two additions
LENSAR said Friday that it has named Charlie Federico and Carmen Bringgold to its board of directors. Federico was the president and CEO of Orthofix International while Bringgold is the chief financial officer and senior vice president of commercialization at NxThera. Based in Orlando, Florida, LENSAR is a developer of laser systems for cataract surgery. Its backers include PDL BioPharma, Aisling Capital, Florida Growth and Florida Opportunity Funds.
- Dermira fetches $51 mln Series C
Dermira, a Redwood City, Calif-based maker of medical dermatology products, has closed $51 million in Series C financing. The investors included Bay City Capital, New Enterprise Associates, Canaan Partners, UCB S.A., Apple Tree Partners, Aisling Capital, Rock Springs Capital and Sabby Capital. Leerink Partners was the placement agent for the financing. In addition to the funding, Dermira has named Andrew Guggenhime as chief operating officer and chief financial officer; Christine Conroy as senior vice president of regulatory affairs; and Christine Ring as vice president of legal. It has also appointed David E. Cohen, Matthew Fust, Mark McDade and William Ringo to its board of directors.
PSERS's struggling late-stage portfolio shunned brand-name funds: VCJThe Pennsylvania Public School Employees’ Retirement System favored late-stage managers, dodged brand name funds, pledged money inconsistently and is struggling with the returns on its venture investments, affillate magazine Venture Capital Journal reports.
Fund performance: Struggling late-stage portfolio shunned brand-name fundsTenaya, Aisling, LLR top PSERS’ venture holdings